Alkermes (ALKS) , an Ireland-based biotech , swung to a Q3 profit of 34 cents a share, beating by 11 cents, from a year-ago loss of 11 cents, as revenue rose 8.2% to $135.9 mil, above views of $130.8 mil. It raised its full-year profit guidance, which implies Q4 EPS of 9-23 cents, the midpoint below Wall Street views of 18 cents. Shares rallied 5.2%.
Stocks rose on Tuesday, with the Dow and the S&P 500 closing at new all-time highs as comments from Federal Reserve …